Nothing was found on your request

valeant pharmaceuticals international inc

Breakingviews: Valeant’s Struggles Are a Bad Omen for the Entire Industry

Intensifying pressure stands to upend business models heavily dependent on raising prices.
William Ackman’s 2016 Fortune: Down, but Far From Out

William Ackman’s 2016 Fortune: Down, but Far From Out

William Ackman, chief executive of Pershing Square Capital Management. “I have an enormous stomach for volatility,” Mr. Ackman said last week.
Former Valeant and Philidor Executives Charged in Kickback Scheme

Former Valeant and Philidor Executives Charged in Kickback Scheme

Federal prosecutors outlined on Thursday the kickback scheme that they say involved the former Valeant executive Gary Tanner Philidor’s former chief, Andrew Davenport.

White Collar Watch: Kickback Case Questions Whether Valeant Was Victim or Participant

The case appears to be a straightforward tale of avarice, but the Justice Department may have a difficult time proving the charges.

Street Scene: Documents Open Curtain on Boardroom Drama at Valeant

A Senate committee report shows how the hedge fund billionaire William Ackman turned on a chief executive he had long supported.

Street Scene: In Valeant Stake, Still Unresolved Questions for Activist Investor

The billionaire investor William A. Ackman knew about Valeant’s hostile bid for Allergan and profited from it, raising questions that could come back to haunt him.
William Ackman Sells Pershing Fund’s Stake in Valeant

William Ackman Sells Pershing Fund’s Stake in Valeant

William A. Ackman, right, announced Monday that his firm, Pershing Square Capital Management, had sold its stake — about 27 million shares — in Valeant Pharmaceuticals International.
William Ackman Sells Pershing Fund’s Stake in Valeant

William Ackman Sells Pershing Fund’s Stake in Valeant

William A. Ackman, right, announced Monday that his firm, Pershing Square Capital Management, had sold its stake — about 27 million shares — in Valeant Pharmaceuticals International.
Hedge Fund Titan’s Surefire Bet Turns Into a $4 Billion Loss

Hedge Fund Titan’s Surefire Bet Turns Into a $4 Billion Loss

William A. Ackman in 2015. Last week, he and his investors in funds run by Pershing Square Capital Management swallowed a $4 billion loss on Valeant Pharmaceuticals International.

How a Big Wager on Valeant Played Out

A recap of the major events during Pershing’s association with Valeant.
Valeant Bet Was a ‘Huge Mistake,’ Hedge Fund Chief Ackman Says

Valeant Bet Was a ‘Huge Mistake,’ Hedge Fund Chief Ackman Says

The billionaire hedge fund manager William A. Ackman says his investment in Valeant Pharmaceuticals International has “damaged the record of success of our firm.”
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a
Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

Patients Eagerly Awaited a Generic Drug. Then They Saw the Price.

A Teva Pharmaceutical drug manufacturing facility in Jerusalem. The company announced earlier this month it would sell a generic version of the drug Syprine at a lower price, but it’s hardly a
Ackman Ends His 5-Year Fight With Herbalife

Ackman Ends His 5-Year Fight With Herbalife

William A. Ackman, the head of Pershing Square Capital Management, had attacked the practices of Herbalife, the nutritional supplement company, in the hope that federal action would sink its stock.
Valeant, Distancing Itself From Its Past, Will Change Its Name to Bausch Health

Valeant, Distancing Itself From Its Past, Will Change Its Name to Bausch Health

Valeant’s headquarters in Bridgewater, N.J. The drug maker’s new name, Bausch Health Companies, will take effect in July, the company said.